


Supplementary Information

Mesenchymal Stromal Cells-Derived β 2-Microglobulin Promotes Epithelial–Mesenchymal Transition of Esophageal Squamous Cell Carcinoma Cells

Junjie Wang ^{1,#} Weilin Yang ^{2,3,4,#}, Tao Wang ^{1,#}, Xiaoyong Chen ¹, Jiancheng Wang ¹, Xiaoran Zhang ¹, Chuang Cai ¹, Beilong Zhong ⁵, Jiabin Wu ², Zhenguang Chen ^{2,3,4,*}, Weijun Huang^{1,*} and Andy Peng Xiang ^{1,6,7,*}


Supplementary Figure S1: Construction of MSCs cell line with B2M knock down

Immunofluorescence study revealed the GFP fluorescence expression in MSC^{NTC} and MSC^{shB2M} cells which indirectly reflected the interference efficient of lentivirus system. Results were confirmed by qPCR and western blots analysis after passaging cells. Scales bars, 100 μ m.



Supplementary Figure S2: Protein level of secreted B2M tested by ELISA kit


Secreted B2M level in supernatant of TE-1/Eca109/MSc cells were tested with a commercial ELISA kit (SEA260Hu, Cloud-Clone Corp). We found that protein level of secreted B2M of MSC was almost five to ten times higher than that of ESCC cell lines (TE-1: 3.75 ± 0.34 ng/ml, Eca109: 7.92 ± 1.04 ng/ml, MSC: 30.41 ± 2.93 ng/ml, data were averaged as mean \pm S.D. per 10^7 cells, n = 3)



Supplementary Figure S3: Representative negative surface markers of MSC^{NTC} and MSC^{shB2M}


The results of the flow cytometry analysis revealed that MSC^{NTC} and the MSC^{shB2M} cells did not express surface markers CD34 and CD45, which was similar to wild-type MSCs.

CD34 (550761, BD Pharmingen), CD45 (560975, BD Pharmingen)




Supplementary Figure S4: Representative image of tumor spheroid


Representative image of spheroid formed by TE-1 cells in a modified serum-free medium. Spheroids which have more than 50µm in diameter are included in the statistics. Scales bars, 200µm.



Supplementary Figure S5: Original western blot scanning document of Figure 1





Marked sections with red lines were presented in the manuscript.








Supplementary Figure S6: Original western blot scanning document of Figure 2

Marked sections with red lines were presented in the manuscript.






Supplementary Figure S7: JAK2 inhibitor sabotaged the EMT induction of MSC^{NTC}-CM


Western blots analysis in Eca109 cells indicated that IL6/JAK2/STAT3 pathway involved in the EMT process triggered by MSC^{NTC}-CM which could be inhibited by AG490 (T3434, Sigma-Aldrich). Blocking B2M in MSCs partially inhibited the expression of snail but barely affected phosphorylated STAT3.

Original western blot scanning document were attached.



2015-03-17 Ecal9 (2015-01-22 蛋G)
Vimentin 76kd (c) Ab61939 Rabbit


Ab61939 BSA NTC Con



vimentin

2015-04-01 p-STAT3 Ecal9
p-STAT3 (Tyr705) CST#9131 Rabbit 79/86kd 1:500
抗体来自中山三院黄昌昌(免疫研究所) RT. 3h
+4°C O.N


Ab9131 BSA NTC Con



p-STAT3

2015-04-01 Ecal9 Snail
snail 27kd CST#3879P 1:800 Rabbit


Ab3879P BSA NTC Con



snail

2015-03-20 Ecal9 β -actin

Ab6880 BSA NTC Con



β -actin

Supplementary Table S1. Sequences of oligos used for cloning shRNAs

shRNA	Forward	Oligo Sequence
ID	/Reverse	
B2M-1	Forward	TGCCGTGTGAACCATGTGACTTTCTTCCTGTCAAAA
	Oligo	GTCACATGGTTCACACGGTTTTTTC
	Reverse	TCGAGAAAAAACCGTGTGAACCATGTGACTTTTGAC
	Oligo	AGGAAGAAAGTCACATGGTTCACACGGCA
B2M-2	Forward	TGAGGTTTGAAGATGCCGCATTTCTTCCTGTCAAAT
	Oligo	GCGGCATCTTCAAACCTTTTTTTC
	Reverse	TCGAGAAAAAAGGTTTGAAGATGCCGCATTTTGAC
	Oligo	AGGAAGAAATGCGGCATCTTCAAACCTCA

Supplementary Table S2. List of the qRT-PCR primers used in this study

Target Gene	Forward primer	Reverse primer
GAPDH	5'-GAAGGTGAAGGTCGGA GTC-3'	5'-GAAGATGGTGATGGGAT TTC-3'
E-cadherin	5'-CCCACCACGTACAAGGG TC-3'	5'-CTGGGGTATTGGGGGCA TC -3'
N-cadherin	5'-GCGCTGGCACCGTTTT AC-3'	5'-CCTGAGCACGAAGAGT GTAGA-3'
Vimentin	5'-ACGTCAGCAATATGAAA GTGTG-3'	5'-ACCTGTCTCCGGTACTC A-3'
B2M	5'-TGTGCTCGCGCTACTCT- 3'	5'-GTCAACTTCAATGTCGG ATG-3'

Supplementary Table S3. The detail information of 30 cases esophageal cancer patients after resection.

Patient No.	Gender F/M	Age	Differentiation grade	Tumor Stage	B2M IHC result	PFS (month)
824806	F	60	Moderate	IIIB	(-)	8
828887	F	49	Moderate	IIA	(-)	14
848967	F	63	Moderate	IIIA	(-)	9
837978	F	60	Moderate	IIB	(-)	8
857081	F	53	Moderate	IIA	(-)	9
812597	F	69	Moderate	IIIA	(-)	4
824444	F	46	Moderate	IIIB	(-)	6
861532	F	51	Moderate	IIA	(-)	7
827923	F	58	High	IV	(-)	4
834531	F	57	Moderate	IIA	(-)	12
828914	F	63	High	IIIA	(-)	4
831680	F	55	Moderate	IIIA	(-)	5
838666	F	48	Moderate	IIA	(-)	10
837682	F	59	High	IIA	(-)	12
829769	F	72	Moderate	IIA	(-)	12
833668	F	59	Moderate	IIA	(-)	6

819458	F	62	High	IIA	(-)	10
828752	F	41	Moderate	IIA	(-)	10
816156	M	75	High	IIA	(+)	8
852226	F	59	Moderate	IIA	(+)	4
858149	F	60	Moderate	IIA	(+)	6
811757	F	69	Moderate	IIA	(+)	6
818960	M	57	High	IIA	(+)	2
817356	F	64	High	IIA	(+)	12
816106	M	79	Moderate	IV	(+)	6
846722	M	73	Moderate	IIA	(+)	4
827438	M	66	Moderate	IIIA	(+)	6
818887	M	62	Moderate	IIA	(+)	10
845577	F	64	Moderate	IIB	(+)	3
860896	M	54	Moderate	IIIA	(+)	2
